Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Share this content:
Neoadjuvant Dose Dense Gemcitabine and Cisplatin (DD GC) In Patients With Muscle-Invasive Bladder Cancer

Sponsors and Collaborators
Memorial Sloan-Kettering Cancer Center

Contact
Dean Bajorin, MD
646-422-4333

Jonathan Rosenberg, MD
646-422-4461

Principal Investigator
Dean Bajorin, MD, Memorial Sloan-Kettering Cancer Center

ClinicalTrials.gov Identifier
NCT01589094

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters